首页> 外文OA文献 >Neoadjuvant Chemoradiotherapy And Surgery Compared With Surgery Alone In Squamous Cell Carcinoma Of The Esophagus [radioterapia E Quimioterapia Neoadjuvantes E Cirurgia Comparado Com A Cirurgia No Tratamento Do Carcinoma Epidermoide Do Esôfago]
【2h】

Neoadjuvant Chemoradiotherapy And Surgery Compared With Surgery Alone In Squamous Cell Carcinoma Of The Esophagus [radioterapia E Quimioterapia Neoadjuvantes E Cirurgia Comparado Com A Cirurgia No Tratamento Do Carcinoma Epidermoide Do Esôfago]

机译:食管鳞状细胞癌的新辅助放化疗和单独手术的比较

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Context - Despite progress in recent years in methods of diagnosis and surgical treatment of esophageal cancer, there is still controversy about the benefits from neoadjuvant chemoradiotherapy. Objective - To analise the survival of patients submitted to esophagectomy for squamous cell carcinoma of the esophagus with or without neoadjuvant chemoradiotherapy. Method - A retrospective, non-randomized study conducted using the medical charts of patients operated for squamous cell carcinoma of the esophagus at the School of Medical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil between 1979 and 2006. The Kaplan-Meier analysis was used to calculate survival curves and the log-rank test to compare data in each group. The significance level was settled as 5%. Results - A total of 123 patients were evaluated in this study, divided into three groups: I - 26 (21.2%) patients submitted to esophagectomy alone; II - 81 (65.8%) patients submitted to neoadjuvant radiotherapy plus esophagectomy and III - 16 (13%) patients submitted to neoadjuvant chemoradiotherapy plus esophagectomy. A statistically significant survival was recorded between the groups (log rank = 6.007; P = 0.05), survival being greatest in the group submitted to neoadjuvant chemoradiotherapy, followed by the group submitted to neoadjuvant radiotherapy compared to the group submitted to esophagectomy alone as the initial treatment of choice. Conclusion - Radiotherapy and chemotherapy neoadjuvants in patients with squamous cell carcinoma of the esophagus offers benefits and increases survival.
机译:背景-尽管近年来在食管癌的诊断和外科治疗方法方面取得了进展,但新辅助放化疗的益处仍存在争议。目的-为了分析接受食管鳞状细胞癌伴或不伴新辅助放化疗的食管癌患者的生存率。方法-1979年至2006年之间,在巴西圣保罗坎皮纳斯大学坎普纳斯分校(UNICAMP)医学院对食管鳞状细胞癌手术患者的病历进行了一项回顾性非随机研究。使用Kaplan-Meier分析计算生存曲线,并采用对数秩检验比较各组数据。显着性水平定为5%。结果-本研究共评估了123例患者,分为三组:I-仅接受食管切除术的患者26例(21.2%); II-81(65.8%)例接受新辅助放疗+食管切除术,III-16(13%)例接受新辅助放化疗+食管切除术。两组之间记录有统计学意义的存活率(log rank = 6.007; P = 0.05),与最初单独接受食管切除术的组相比,接受新辅助放化疗的组的生存率最高,其次是接受新辅助放疗的组。治疗的选择。结论-食管鳞状细胞癌患者的放疗和化疗新辅助治疗可带来益处并提高生存率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号